InvestorsHub Logo

joboggi

09/29/14 4:23 PM

#108836 RE: joboggi #108833

I would encourage you to write to the company. It is clear to me based on reading the literature, that they knew about calpain before any agreement with AMBS. I am not a patent attorney, and so I would encourage you to write to the company about the other compounds. My experience tells me that MANF has nothing to do with calpain, or whatever compound Fumi is pursuing.

Now, depending on the circumstances, I have seen companies fight over issues like this. So I would like to hear what AMBS has to say. I have rarely if ever seen the company win however.